Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin ’s Lymphoma: A Systematic Review and Meta-analysis

ConclusionThis systematic review and conventional meta-analysis demonstrated the overall similarity of the long-term efficacy and safety of biosimilar rituximab to those of originator rituximab in RA and NHL patients by combining direct evidence from head-to-head trials.PROSPERO registration No. CRD42019125138.

Source: BioDrugs - August 23, 2019 Category: Drugs & Pharmacology Source Type: research